irinotecan has been researched along with Intestinal Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, M; Bando, H; Hara, K; Honda, K; Kadowaki, S; Kato, K; Kumanishi, R; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M | 1 |
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| Ames, MM; Foster, NR; Goetz, MP; Hobday, TJ; Horvath, LE; Jatoi, A; Mahoney, MR; McWilliams, RR; Meyers, JP; Murray, JA; Schneider, DJ; Smyrk, TC | 1 |
| Boku, N; Hamaguchi, T; Higuchi, K; Honma, Y; Iwasa, S; Kato, K; Shoji, H; Takashima, A; Yamaguchi, T | 1 |
| Boudreaux, JP; Ramirez, RA; Thiagarajan, R; Thomas, KEH; Voros, BA; Woltering, EA | 1 |
| Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Saito, S; Shitara, K; Tani, Y; Watanabe, A | 1 |
| Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Yang, L; Zhang, X; Zhou, J | 1 |
| Abe, T; Fukushima, T; Hamaguchi, Y; Masui, H; Mogaki, M; Nagahori, K; Nagahori, Y | 1 |
| Chin, K; Hatake, K; Konishi, F; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T | 1 |
| Eguchi-Nakajima, T; Hamaguchi, T; Hirashima, Y; Kato, K; Morizane, C; Okita, N; Ono, M; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y | 1 |
| Dasanu, CA; Trikudanathan, G | 1 |
| Fratto, ME; Galluzzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Boku, N; Honma, Y; Kato, S; Kawai, H; Morita, S; Nishina, T; Suenaga, M; Taguri, M; Takahashi, H; Tamura, F; Tsushima, T; Ueda, S | 1 |
| Zhang, L | 1 |
| Dubois, RN; Hatakeyama, N; Horikawa, Y; Jin, M; Komatsu, K; Matsuhashi, T; Odashima, M; Ohba, R; Otaka, M; Oyake, J; Wada, I; Watanabe, S | 1 |
| Caron, P; Liu, D; Patel, S; Seiter, K | 1 |
| Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA | 1 |
2 review(s) available for irinotecan and Intestinal Neoplasms
| Article | Year |
|---|---|
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Intestinal Neoplasms; Irinotecan; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Stomach Neoplasms | 2019 |
Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan | 2010 |
3 trial(s) available for irinotecan and Intestinal Neoplasms
| Article | Year |
|---|---|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Care Facilities; Capecitabine; Databases, Factual; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2017 |
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cisplatin; Female; Humans; Induction Chemotherapy; Intestinal Neoplasms; Irinotecan; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2017 |
12 other study(ies) available for irinotecan and Intestinal Neoplasms
| Article | Year |
|---|---|
Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Intestinal Neoplasms; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2019 |
[A Case of Choriocarcinoma of the Small Intestine with Multiple Lung and Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Humans; Intestinal Neoplasms; Irinotecan; Liver Neoplasms; Male | 2018 |
[Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastroscopy; Humans; Intestinal Neoplasms; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Vitamin B Complex | 2009 |
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Intestinal Neoplasms; Irinotecan; Jejunal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis | 2008 |
Cetuximab in small bowel adenocarcinoma: a new friend?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Female; Humans; Immunotherapy; Intestinal Neoplasms; Intestine, Small; Irinotecan; Male; Middle Aged; Survival | 2010 |
Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Japan; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Retrospective Studies | 2012 |
[Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Female; Humans; Intestinal Neoplasms; Irinotecan; Male; Middle Aged | 2003 |
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Cyclooxygenase 2; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Intestinal Mucosa; Intestinal Neoplasms; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Rats; Signal Transduction; Tumor Cells, Cultured | 2007 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 2007 |
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survival; Deoxyuracil Nucleotides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Thymidylate Synthase; Thymine Nucleotides; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |